The extracorporeal hyperthermia perfusion for the treatment of Lyme disease

The extracorporeal hyperthermia perfusion for the treatment of Lyme disease

The combination therapy method “EHP” shows a new treatment option for Lyme disease patients.

The number of Lyme disease, neuro-borreliosis and other ailments and diseases related to Borrelia has been increasing for decades. In the 1990s, medicine was still faced with a mystery and accordingly, false diagnoses were frequently made and the symptoms and sufferings of the patients were causally unrecognised. Today, Lyme disease and its subspecies is a fairly recognised disease, because various forces have been (and still are) trying to trivialise Lyme disease or even dismiss it as a figment of our imagination.

But the figures speak for themselves: According to the state of affairs of the Scientific Service of the German Bundestag (source: German Bundestag – file number WD 9-3000-012/17), which is based on the data of the in-patient treated cases of Lyme disease reported from the individual German states, according to expert estimation, there were already 214,000 patients in Germany in 2007 and 2008 – per year!

Panacea Antibiosis – overestimated, not scientifically supported and with intensive side effects.

But treat it like Lyme disease? Currently, the most common and applied treatment is the short or long-term treatment with antibiotics. However, as studies show (and this is also reported in the state of affairs of the German Bundestag), the statement is not justified that antibiotics, be they short or long term or administered several times, are successful. Rather, several studies have shown that embolisms, toxic reactions, anaemia and internal bleeding occurred as side effects in the test persons.

Furthermore, Lyme disease is usually a mixed infection of Ehrlichia, Cytomegaly, Bornavirus, EBV, Babesia and other pathogens. This is one reason why conventional antibiotic treatment often does not lead to success. In addition, the relevant pathogens can retreat into a kind of complete dormancy and become virtually “invisible”, so that they are practically undetectable for laboratory investigations.

A new, promising approach: extracorporeal hyperthermia perfusion – in short: EHP.

In recent years, a new, combined therapy method has been developed which could possibly set a milestone in the treatment of Lyme disease – and not only for this disease. The extracorporeal hyperthermia perfusion (EHP) follows a holistic approach, which combines the possibilities of today’s “high-tech medicine” with the oldest knowledge of medicine: It is our own organism, which knows how to successfully defend itself against enemies – be it viruses, bacteria, other pathogens or even borrelia. Our own immune system is a well-balanced arsenal, but in case of illness it simply needs help from outside.

EHP therefore combines procedural elements of artificial fever production (hyperthermia), various types of blood purification (haemoperfusion and apheresis) and increasing the oxygen supply in the bloodstream (oxyvenation) in a single procedure. The aim is to help the body to free itself from its burdens as efficiently and with as few side effects as possible and to allow the immune system to resume its own work at full strength.

In the case of extracorporeal hyperthermia perfusion (EHP), the success rate is now very well documented. The author of this report has been in personal contact with patients undergoing therapy, in some cases for more than 10 months, and has experienced the therapy, which incidentally lasts 3 – 4 hours on a one-off basis, as an observer on site herself down to the last detail. If the patients were not well, this report would not exist.

Further information on extracorporeal hyperthermia perfusion can be found on our website in the “EHP” section and on our website

Zentrum der Erweiterten Medizin